Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 289
- 试验地点
- 1
- 主要终点
- Examine whether knowledge of ctDNA negativity influences patient decision-making
研究概览
简要总结
This study will examine how ctDNA and additional prognostic genomic information in patients with early stage breast cancer might influences patient decision- making regarding systemic therapy options.
详细描述
This study is an electronically delivered, one time cross sectional survey study. The investigators want to understand how patients with triple negative breast cancer at high risk for disease recurrence will prioritize additional benefit over toxicity when considering treatment options, and if their knowledge of ctDNA positivity versus negativity will further shift this balance toward benefit.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Self- reported history of non-metastatic breast cancer
- •Self- reported history of receiving chemotherapy for breast cancer
- •Self- reported history of chemotherapy completed at least 6 months ago but no more than 10 years ago
- •Able to complete an online survey
- •English speaking
排除标准
- 未提供
结局指标
主要结局
Examine whether knowledge of ctDNA negativity influences patient decision-making
时间窗: Once all surveys in the sample size are completed, 6 months anticipated
Ratings- based analysis will be used to examine whether knowledge of ctDNA negativity increases patient acceptability (and if so, by how much) of no therapy in the adjuvant setting, compared to standard of care capecitabine.
次要结局
- Estimate at what degree of benefit a given treatment would be acceptable to patients(Once all surveys in the sample size are completed, 6 months anticipated)
研究者
Tarah J Ballinger, MD
Assistant Professor of Clinical Medicine
Indiana University